Philogen and Sun Pharma seek EMA approval for melanoma therapy
Details : Announced the filing of a marketing authorisation application with the European Medicines Agency for Nidlegy, an investigational neoadjuvant therapy, for locally advanced, fully resectable melanoma.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : Onfekafusp Alpha,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Philogen Updates on Ph III Trial of Onfekafusp Alfa in Advanced Soft Tissue Sarcoma
Details : L19TNF (onfekafusp alfa), a homotrimer peptide fused to human TNF, is being evaluated with doxorubicin for first-line treatment of advanced or metastatic soft tissue sarcoma.
Product Name : Fibromun
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : Onfekafusp Alpha,Doxorubicin Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sun Pharma, Philogen Ink Licensing Deal for Cancer Drug Firbomun
Details : The agreement aims for the commercialisation of Fibromun (onfekafusp alfa), being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.
Product Name : Fibromun
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 10, 2024
Details : Nidlegy (bifikafusp alfa & onfekafusp alfa) is designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF which are manufactured independently, and which are mixed prior to intralesional administration.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
October 16, 2023
Sun Pharma and Philogen Sign Licence Agreement for Anti-Cancer Therapy
Details : Under the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy (bifikafusp alfa), a new anti-cancer biopharmaceutical, being developed by Philogen for melanoma and non-melanoma skin cancers, in the territories of Europe, Australia an...
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Undisclosed
May 30, 2023
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RAD1901 (elacestrant) is an investigational selective estrogen receptor degrader (SERD). Preclinical studies indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Submission supported by results from pivotal Phase 3 EMERALD study of RAD1901 (elacestrant) showing statistically significant efficacy over current standard-of-care (SOC) medications for both overall study population and patients whose tumors harbor an E...
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 08, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elacestrant (RAD1901), if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union.
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nidlegy (bifikafusp alfa) is combination of the immunocytokines L19IL2 and L19TNF, which is being developed as intralesional treatment for patients with advanced locoregional melanoma and non-melanoma skin cancers.
Product Name : Nidlegy
Product Type : Protein
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elacestrant (RAD1901), is an investigational selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer.
Product Name : RAD1901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : Elacestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Radius Health
Deal Size : Inapplicable
Deal Type : Inapplicable